Estudio de la progresión del cáncer de próstata incidental según el tipo de tratamiento aplicado

Lecumberri, S Napal; Couso, Francisco Javier Lameiro; Navarro, Celina; Dorronsoro, M. Gómez; Liñero, B. Larrinaga; Aznar, Amadeo

doi:10.1016/s0210-4806(07)73734-8

Cited by 6 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patients that were excluded from the study and did have persistent uptake did not have biopsy nor had their serum PSA evaluated due to presence of aggressive underlying malignancy such as metastatic melanoma and lung cancer. These patients may succumb to their underlying malignancy in a short period of time; uptake in the prostate has no clinical relevance as patients with low risk (Gleason lower than 6) can survive up to 16 years and with high risk prostate cancer (Gleason higher than 7) can survive up to 6 years [18]. However, patients with high Gleason score do require aggressive therapy [18].…”

Section: Discussionmentioning

confidence: 99%

“…Nonetheless, no matter what type of uptake is seen in patients who have nonaggressive underlying malignancies, this finding should be further evaluated, as incidentally found prostate cancers can also cause mortality in this once thought nonlethal disease [19, 20] and the treatment may be based on the grade, stage, and the age of the patient [18, 21]. Studies have shown survival benefit in patients who have incidental prostate cancers resected during cystoprostatectomy for bladder cancer [22] and such studies need to be performed in the setting of other malignancies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

Bhosale

Balachandran

Vikram

et al. 2013

International Journal of Molecular Imaging

View full text Add to dashboard Cite

Purpose. To determine the clinical significance of unexpected, abnormal FDG uptake in the prostate in patients undergoing FDG-PET/CT for staging of other primary malignancies without a prior history of prostate carcinoma. Methods. Retrospective search of FDG-PET/CT studies to identify patients with unexpected, abnormal FDG uptake in the prostate gland, who underwent subsequent biopsy, was performed. 26 patients were identified. Images were reviewed to determine the pattern of uptake within the prostate (focal or diffuse) and maximum standardized uptake value (SUVmax). PSA and Gleason scores were recorded. Results. 15/26 (58%) patients were found to have prostate carcinoma. Gleason scores ranged from 6 to 9.9. There was no statistical difference in the pattern of uptake (focal versus diffuse) or the SUVmax. Serum PSA levels with cancer (range, 2–26.8 ng; mean, 10.2 ng) and those without cancer (range, 2–10.5 ng; mean, 2.2 ng) were statistically significant (P < 0.007, Wilcoxon rank sum test). Conclusions. Patients with abnormal uptake in the prostate have a 58% likelihood of occult prostate cancer. In the setting of elevated serum PSA levels, abnormal prostate uptake should therefore be viewed with suspicion and a urology consult should be obtained; however, it is irrelevant in patients with underlying aggressive malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

Bhosale

Balachandran

Vikram

et al. 2013

International Journal of Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…Incidental Prostatic carcinoma (IPCa) is defined as a "cancer which lacks apparent neoplastic symptoms or cancer which is unusually detected by microscopic examination of resected tissue that had been previously diagnosed as benign. 11 Different screening programs in the past have led to detection of prostate carcinoma but, With the use of traditional and latest modern screening methods and techniques for PAC, including digital rectal examination (DRE), measurement of prostate-specific antigen (PSA), and transrectal ultrasound (TURS) and prostate biopsy, have not only reported better diagnosis of PAC but also an increase in the incidence of PAC. 12 Today, PCa is more frequently being diagnosed in asymptomatic patients with localized disease.…”

Section: Disscusionmentioning

confidence: 99%

To determine the frequency of prostate malignancy in patients with clinically benign prostate

Qureshi

Sohail

Sahito³

et al. 2019

TPMJ

View full text Add to dashboard Cite

To see the frequency of prostatic malignancy in patients presenting with clinically benign prostate. Study Design: Descriptive case series. Setting: Department of Urology at Peoples University of Medical and Health Sciences for Women / Hospital Nawabshah. Period: Fifteen Months, From October 2016 to December 2017. Materials and Methods: A total of 100 patients who presented with the clinically benign prostate in Urology OPD were enrolled. All concern data regarding Age, mode of presentation (lower urinary tract symptoms with IPSS score/ Acute retention of urine), comorbid, clinical examination findings, pre voided and post-void residual urine determination (on ultrasonography) were entered. The laboratory investigation includes complete blood count, urea, creatinine, random blood sugar (RBS), urine DR and CS, coagulation profile were performed before TURP.TURP performed under spinal anesthesia. After TURP the prostatic tissue chips were sent for histopathology as a routine. Data was analyzed through SPSS Version 20.0. Results: The average age of males was 71.38± 7.19 yrs. Most of the patients with (IPSS 20-35) BPH have lower urinary tract symptoms (both obstructive and irritative). DRE was done in all patients to estimate the size of the prostrate, it was varying from grade 1 enlarged n= 27(27%), grade 2 enlarged n= 36(36%), to grade 3 enlarged in n=37(37%). There were 3 (3%) cases reported to have prostate cancer, with findings confirmed by biopsy of TURP Specimen. There was no mortality seen in our study. The clinical presentation of patients, grades of enlargements on DRE and IPSS however, demonstrated no correlation. Conclusion: BPH is more common between 60-80yrs. When patient undergo TURP or open prostatectomy, every specimen should be sent for biopsy because prostate cancer is only confirmed by biopsy, so that prostate cancer is detected early Radiology & PSA values are supportive in their role but are not true diagnostic. Prostatic cancer is a significant morbid condition, so effective measures should be taken to detect prostatic cancer, so that patient can be properly treated according to the stage.

show abstract

“…Incidental PCa (IPCa) is defined as a “cancer which lacks apparent neoplastic symptoms or cancer which is unusually detected by microscopic examination of resected tissue that had been previously diagnosed as benign.” 9 Today, PCa is more frequently being diagnosed in asymptomatic patients with localized disease. Owing to early diagnosis, more cases of focal PCa or IPCa are diagnosed.…”

Section: Introductionmentioning

confidence: 99%

“…Owing to early diagnosis, more cases of focal PCa or IPCa are diagnosed. 9 , 10 There is also a population group composed of patients with obstructive lower urinary tract symptoms (LUTS) that are probably an outcome of BPH. These patients do not manifest with clinical symptoms nor does the disease show up on digital rectal examination (DRE), and they often have normal PSA levels.…”

Section: Introductionmentioning

confidence: 99%

Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran

Abedi

Fallah-Karkan

Ranjbar

et al. 2018

RRU

View full text Add to dashboard Cite

ObjectiveIncidental prostate cancer (IPCa) is defined as a symptom-free cancer unexpectedly discovered upon microscopic examination of resected tissue. The aim of this study was to report the correlation between some specific clinical criteria in patients incidentally diagnosed with prostate cancer (PCa) during transurethral resection of the prostate (TURP) or open prostatectomy (OP) after clinically suspected benign prostatic hyperplasia.Patients and methodsThis was a cross-sectional, retrospective study. Data were collected from Shohada-e-Tajrish Hospital database during November 2006 to October 2016. Four hundred and twenty three men suffering from symptomatic benign prostatic hyperplasia who underwent either TURP or OP that provided a prostate specimen were evaluated. The data analysis was performed using Pearson correlation test and independent t-test using SPSS version 20 software.ResultsThe mean age of subjects was 68.74±9.87 years old (45–93 years). The mean prostate specific antigen (PSA) level was 21.47±13.44 ng/mL (0.6–47.1 ng/mL). Results showed that 84 patients (19.9%) had PCa (40 patients who underwent TURP [12.6%] and 44 patients who underwent OP [40.7%] groups). Cut-off point of PSA for detecting IPCa was 3.8 ng/mL in our study, and this showed sensitivity, specificity, negative predictive value, and positive predictive value of 26.08%, 100%, 100%, and 29.79%, respectively. Twenty two patients with cancer had a positive family history for PCa; thus, a significant relationship between familial history of PCa and its occurrence was shown (p=0.0001).ConclusionAccording to the results of this study, the cut-off point for PSA levels in detecting PCa was 3.8 ng/mL, which is similar to that reported by other studies. Familial history of PCa and PSA levels were two predictors in determining the PCa.

show abstract

Estudio de la progresión del cáncer de próstata incidental según el tipo de tratamiento aplicado

Abstract: While in low risk patients watchful waiting represents an acceptable aproaching, it could not be adequate in high risk cases. Hormonotherapy showed no benefit in incidental prostate cancer.

Cited by 6 publications

References 16 publications

What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

To determine the frequency of prostate malignancy in patients with clinically benign prostate

Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran

Contact Info

Product

Resources

About